Schrödinger, Inc. (SDGR)

US — Healthcare Sector
Peers: VEEV  DOCS  AMWL  GEHC  TDOC  TXG  PGNY    CERT  HQY  RCM  ACCD 

Automate Your Wheel Strategy on SDGR

With Tiblio's Option Bot, you can configure your own wheel strategy including SDGR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SDGR
  • Rev/Share 3.1549
  • Book/Share 5.1124
  • PB 4.982
  • Debt/Equity 0.311
  • CurrentRatio 3.4504
  • ROIC -0.326

 

  • MktCap 1868909261.0
  • FreeCF/Share 0.3033
  • PFCF 84.3409
  • PE -9.6812
  • Debt/Assets 0.1563
  • DivYield 0
  • ROE -0.4474

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 2
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
SDGR
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc.("Schrödinger" or the "Company") (NASDAQ:SDGR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
SDGR
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. (“Schrödinger” or the “Company”) (NASDAQ: SDGR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Shareholders to Connect
SDGR
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASDAQ:SDGR). Investors who purchased Schrödinger securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SDGR.

Read More
image for news Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Shareholders to Connect
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
SDGR
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc.("Schrödinger" or the "Company") (NASDAQ:SDGR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
SDGR
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc.("Schrödinger" or the "Company") (NASDAQ:SDGR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Shareholders to Reach Out
SDGR
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / June 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASDAQ:SDGR). Investors who purchased Schrödinger securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SDGR.

Read More
image for news Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Shareholders to Reach Out
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
SDGR
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. (“Schrödinger” or the “Company”) (NASDAQ: SDGR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities Investigation
SDGR
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / June 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASDAQ:SDGR). Investors who purchased Schrödinger securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SDGR.

Read More
image for news Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities Investigation
Fraud Investigation Opened: Levi & Korsinsky Investigates Schrdinger, Inc. (SDGR) on Behalf of Shareholders
SDGR
Published: May 30, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Schrdinger, Inc. ("Schrdinger, Inc.") (NASDAQ:SDGR) concerning possible violations of federal securities laws. Schrödinger issued a press release on May 20, 2025, "announcing that the company and Geoffrey Porges, MBBS.

Read More
image for news Fraud Investigation Opened: Levi & Korsinsky Investigates Schrdinger, Inc. (SDGR) on Behalf of Shareholders
Schrdinger, Inc. (SDGR) Under Investigation for Potential Securities Law Violations - Contact Levi & Korsinsky Today
SDGR
Published: May 29, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Schrdinger, Inc. ("Schrdinger, Inc.") (NASDAQ:SDGR) concerning possible violations of federal securities laws. Schrödinger issued a press release on May 20, 2025, "announcing that the company and Geoffrey Porges, MBBS.

Read More
image for news Schrdinger, Inc. (SDGR) Under Investigation for Potential Securities Law Violations - Contact Levi & Korsinsky Today
Ongoing Schrdinger, Inc. (SDGR) Investigation: Protect Your Rights - Contact Levi & Korsinsky
SDGR
Published: May 28, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Schrdinger, Inc. ("Schrdinger, Inc.") (NASDAQ:SDGR) concerning possible violations of federal securities laws. Schrödinger issued a press release on May 20, 2025, "announcing that the company and Geoffrey Porges, MBBS.

Read More
image for news Ongoing Schrdinger, Inc. (SDGR) Investigation: Protect Your Rights - Contact Levi & Korsinsky
Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities Investigation
SDGR
Published: May 28, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASDAQ:SDGR). Investors who purchased Schrödinger securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SDGR.

Read More
image for news Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities Investigation
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
SDGR
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc.("Schrödinger" or the "Company") (NASDAQ:SDGR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?
RXRX, SDGR
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Neutral

Recursion Pharmaceuticals and Schrodinger leverage their respective AI drug discovery platforms to potentially develop distinguished therapeutic candidates.

Read More
image for news RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Stockholders to Learn More About the Investigation
SDGR
Published: May 23, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASDAQ:SDGR). Investors who purchased Schrödinger securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SDGR.

Read More
image for news Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Stockholders to Learn More About the Investigation
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SDGR
Published: May 23, 2025 by: Business Wire
Sentiment: Neutral

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on May 21, 2025, the company granted restricted stock units (RSUs) with respect to 7,051 shares of the company's common stock to seven newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to.

Read More
image for news Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Investors to Inquire about Securities Investigation
SDGR
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASDAQ:SDGR). Investors who purchased Schrödinger securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SDGR.

Read More
image for news Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Investors to Inquire about Securities Investigation
Schrödinger to Present at Jefferies Global Healthcare Conference
SDGR
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference. The live presentation will take place on Wednesday, June 4, 2025 at 1:25 p.m. E.T. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational.

Read More
image for news Schrödinger to Present at Jefferies Global Healthcare Conference
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
SDGR
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. ("Schrödinger" or the "Company") (NASDAQ:SDGR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
Schrödinger: Regulatory Tailwinds Are Supportive Of Continued Strong Growth (Rating Upgrade)
SDGR
Published: May 20, 2025 by: Seeking Alpha
Sentiment: Positive

Schrödinger delivered strong Q1 results, with robust software growth and improving margins, despite a tough macro environment. Regulatory changes, especially the FDA's move away from animal testing, could create a meaningful tailwind for Schrödinger's predictive toxicity software initiative. Schrödinger's Drug Discovery business also continues to progress, but this likely won't matter until the company generates positive later stage clinical data.

Read More
image for news Schrödinger: Regulatory Tailwinds Are Supportive Of Continued Strong Growth (Rating Upgrade)
Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma
SDGR
Published: May 14, 2025 by: Business Wire
Sentiment: Neutral

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that initial Phase 1 clinical data for SGR-1505, its investigational MALT1 inhibitor, will be presented at the European Hematology Association Annual Congress, taking place June 12 - 15, 2025, in Milan, Italy. Additional data from this trial will be presented at the International Conference on Malignant Lymphoma, taking place June 17 - 21, 2025, in Lugano, Switzerland. The Phase 1 study is designed to evaluate the safet.

Read More
image for news Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Tops Revenue Estimates
SDGR
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to loss of $0.76 per share a year ago.

Read More
image for news Schrodinger, Inc. (SDGR) Reports Q1 Loss, Tops Revenue Estimates
Schrödinger, Inc. (SDGR) Q1 2025 Earnings Call Transcript
SDGR
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral

Schrödinger, Inc. (NASDAQ:SDGR ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations & Corporate Affairs Ramy Farid - President & Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President, R&D & Therapeutics Conference Call Participants Michael Yee - Jefferies Brendan Smith - TD Cowen Mani Foroohar - Leerink Partners Evan Seigerman - BMO Capital Markets Michael Ryskin - Bank of America Scott Schoenhaus - KeyBanc Vikram Purohit - Morgan Stanley Operator Thank you for standing by. Welcome to Schrödinger's conference call to review …

Read More
image for news Schrödinger, Inc. (SDGR) Q1 2025 Earnings Call Transcript
Schrödinger Presents New Preclinical Data at AACR Annual Meeting
SDGR
Published: April 28, 2025 by: Business Wire
Sentiment: Neutral

CHICAGO--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) presented preclinical data on SGR-3515, its investigational Wee1/Myt1 co-inhibitor today at the American Association for Cancer Research (AACR) Annual Meeting 2025. The data demonstrated that SGR-3515 has improved anti-tumor activity in preclinical models compared to known Wee1 and Myt1 monotherapy inhibitors. The poster also described how the dosing schedule of SGR-3515 can be optimized to preserve efficacy and minimize target-related.

Read More
image for news Schrödinger Presents New Preclinical Data at AACR Annual Meeting
3 Momentum Stocks That Could Soar Post-Market Volatility
CERT, LOVE, SDGR
Published: April 21, 2025 by: MarketBeat
Sentiment: Negative

While the impact of unanticipated tariff policy changes in early April was market-wide, the recovery has been less even. Despite a major rebound following the sell-off, some firms have been sluggish to reclaim lost ground.

Read More
image for news 3 Momentum Stocks That Could Soar Post-Market Volatility
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SDGR
Published: April 18, 2025 by: Business Wire
Sentiment: Neutral

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on April 16, 2025, the company granted (i) a non-statutory stock option to purchase 3,300 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 12,866 shares of the company's common stock to six newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of.

Read More
image for news Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates
SDGR
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Negative

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.32 per share a year ago.

Read More
image for news Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates

About Schrödinger, Inc. (SDGR)

  • IPO Date 2020-02-06
  • Website https://www.schrodinger.com
  • Industry Medical - Healthcare Information Services
  • CEO Dr. Ramy Farid Ph.D.
  • Employees 891

Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.